A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Who May Qualify: - Diagnosis of ulcerative colitis (UC) established at least 3 months - Moderately to severely active UC assessed by mMS - Inadequate response, loss of response, or intolerance to conventional or advanced therapies for UC Who Should NOT Join This Trial: - Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC - Diagnosis of Crohn's disease or indeterminate colitis - Treatment with an advanced therapy targeted at tumor necrosis factor-like cytokine 1A (TL1a) - Inadequate response, loss of response, or intolerance to treatment of UC with an advanced therapy targeted at IL-12 and/or IL-23 Always talk to your doctor about whether this trial is right for you.